Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V. Hirayama, Cameron J. Turtle, Erik L. Kimble et al.|Blood Advances|2023Cited by 56
Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Lorenzo Iovino et al.|Blood Advances|2024Cited by 11
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Cameron J. Turtle, Emily C. Liang et al.|Blood Advances|2025Cited by 10
T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case SeriesAya Albittar, Alexandre V. Hirayama, Alireza Torabi et al.|Transplantation and Cellular Therapy|2024Cited by 6
Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin LevelsJennifer J. Huang, Jordan Gauthier, Emily C. Liang et al.|Transplantation and Cellular Therapy|2024Cited by 3